- Location
Mike Mahoney
"-
Renal Denervation as a High Blood Pressure Treatment Is Looking Less Exciting by The Day
Jan 23, 2014Renal denervation as a high blood pressure treatment is looking less exciting by the day, with the latest bad news coming from Covidien. The Dublin, Ireland–based medical device giant said Tuesday that it will exit its OneShot renal ...
-
Medtronic's Symplicity System Failed on Efficacy in a Pivotal U.S. Clinical Trial.
Jan 16, 2014Posted in Cardiovascular by Chris Newmarker on January 15, 2014 Boston Scientific CEO Mike Mahoney remains optimistic about renal denervation and the company’s Vessix platform, even though Medtronic’s Symplicity system failed ...
Tags: Boston Scientific, Mike Mahoney, renal denervation, Vessix platform
-
Boston Scientific Enters Into an Agreement to Buy All The Assets of Vessix Vascular
Dec 17, 2012Boston Scientific has entered into a definitive agreement to buy all the assets of Vessix Vascular for an upfront payment of $125m. Under the acquisition, Vessix Vascular will be integrated into Boston Scientific's peripheral ...